JGC
BLUE

J. Goldman & Co’s bluebird bio BLUE Stock Holding History

J. Goldman & Co’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-567
Closed -$772K – 339
2017
Q2 		$772K Sell
567
-730
-56% -$881K 0.04% 225
2017
Q1 		$1.53M Buy
+1,297
New +$1.32M 0.08% 225

Other funds holding BLUE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

J. Goldman & Co's BLUE Position: Q3 2017 in Review

J. Goldman & Co sold out of bluebird bio (BLUE) in Q3 2017, closing a stake of 567 shares — an estimated $772K sold.

J. Goldman & Co first reported a position in BLUE in Q1 2017 and held it in 2 quarters. The position peaked at $1.53M in Q1 2017. 243 funds tracked by Wall St. Rank hold BLUE as of Q3 2017.

  • J. Goldman & Co reported no remaining bluebird bio position as of Q3 2017 after selling out during the quarter.
  • J. Goldman & Co sold 567 bluebird bio shares in Q3 2017, an estimated $772K.
  • J. Goldman & Co first reported a position in bluebird bio in Q1 2017 and held it in 2 quarters.
  • J. Goldman & Co's bluebird bio position peaked at $1.53M in Q1 2017.
  • 243 funds tracked by Wall St. Rank held bluebird bio as of Q3 2017.

Based on J. Goldman & Co's 13F filing for Q3 2017, filed 14 Nov 2017.